Metraipolis › archive › dc_5f259f03349b

Empagliflozin Treatment for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials — Europe PMC PMID:40959362

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40959362
DOI
10.7759/cureus.90205
License (as archived)
solo-consultazione
Archived
2026-11-10T13:50:45.272Z
SHA-256 of the archived text
2f875bc7a479de990fc18c33ffe26bd7d7c90c146d3cdc3b66a93b5ce9762096
Stable URL of this page
https://metraipolis.com/documento/dc_5f259f03349b

How to cite

Empagliflozin Treatment for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials — Europe PMC PMID:40959362 — Europe PMC (en), https://europepmc.org/article/MED/40959362 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5f259f03349b (Metraipolis archive dc_5f259f03349b, sha256 2f875bc7a479de990fc18c33ffe26bd7d7c90c146d3cdc3b66a93b5ce9762096)
BibTeX
@misc{dc5f259f03349b,
  title = {Empagliflozin Treatment for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials — Europe PMC PMID:40959362},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40959362},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5f259f03349b; sha256 2f875bc7a479de990fc18c33ffe26bd7d7c90c146d3cdc3b66a93b5ce9762096},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40959362. Agents can read the archived copy with the MCP tool read_document.